Theralase Technologies' lead compound shown to destroy lung cancer
The latest data comes from pre-clinical research carried out by Dr Kazuhiro Yasufuku and his team in Toronto
Company
Theralase Technologies Inc
CVE:TLT
Theralase Technologies Inc is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers.
80 stories · page 3 of 4
Theralase Technologies moves to second phase in bladder cancer trial
As reported last week, the treatment of the first three patients in the study was a success.
Theralase Technologies shares rocket on TLD-1433 clinical trial findings
The candidate is a light activated photo dynamic compound (PDC)
Theralase's technology lauded in new scientific study
The study, on mice, concluded that low-intensity laser therapy was effective in treating arthritis.
TheraLase Technologies boosted by further patent for lead cancer compound
The biomedical firm received a second patent for its lead anti-cancer compound TLD-1433.
Theralase Technologies boosted as benefits of TLD-1433 outlined at conference
Theralase's president and chief executive said he was delighted about the audience at the conference.
Canada's Theralase qualifies for listing on OTCQX in US
Theralase has met all the requirements of the OTCQX exchange and its shares can now be traded more easily by US investors
Theralase in TLC-2000 rethink as sales fail to meet ambitious targets
Sales in the first quarter rose, but not as quickly as expected, prompting a decision to overhaul the flagship TLC-2000 tissue healing device
Theralase to expand bladder cancer trial after initial success
Theralase's Photo Dynamic Therapy technology is a "search and destroy" treatment for cancer cells
Theralase Technologies continues its journey to clinical-stage
Theralase's pipeline includes numerous highly effective drug candidates, in various advanced stages of preclinical development.
TheraLase Technologies treats third patient with lead cancer compound
The procedure sees Theralase's lead anti-cancer compound put through the urethra into the bladder
Archive
Proactive headlines, including Arizona Silver Exploration, Royal Road Minerals and more
A look at some of the Proactive US headine stories of the day
TheraLase Technologies treats second patient with its lead cancer compound
TheraLase Technologies said a second patient had been treated with its photo dynamic therapy (PDT)
TheraLase Technologies' latest research on anti-cancer compounds to be published
Theralase's photo dynamic compounds (PDCs) are able to localize to cancer cells
TheraLase Technologies welcomes first human testing of its lead cancer compound
TheraLase Technologies Inc revealed its photo dynamic therapy technology had been used for the first time in human clinical testing - a major milestone.
TheraLase Technologies shares up on positive data on lead cancer compound
TheraLase Technologies has received more good news on its lead cancer treating compound
Laser specialist TheraLase Technologies primed for a pivotal year
Unlike many fledgling med-tech companies it is generating revenues and thinks there is scope to significantly increase turnover in the next few years.
Theralase adopts advance notice bylaw
Theralase Technologies Inc said on Tuesday it has adopted bylaw No. 3 to establish a framework for the advance notice of nominations of directors by shareholders of Theralase
Theralase starts enrolling for bladder cancer study
Theralase's Photo Dynamic Therapy division develops specially designed molecules that localize to cancer cells and then when laser light activated, effectively destroy them
Theralase Technologies gets stability boost for cancer treatment
Theralase is aiming for a Phase Ib clinical trial for patients afflicted with Non-Muscle Invasive Bladder Cancer